非增强简化MRI监测TACE后HCC疗效的价值
本研究为单中心回顾性研究,纳入195例肝细胞癌患者共267个TACE治疗后病灶,以钆塞酸二钠增强全序列MRI为参考。研究人员采用LI-RADS辅助征象模拟非增强简化MRI(NC-AMRI),比较其与全序列MRI对TACE后肝内复发的诊断效能。结果显示NC-AMRI诊断准确性中等,但低于全序列MRI。
要点
- NC-AMRI对TACE后活性肿瘤及肝内复发的敏感度、特异度均低于全序列增强MRI。
- NC-AMRI漏诊活性肿瘤或复发时可能延误再治疗决策,报告中需提示其局限。
- 全序列钆塞酸二钠增强MRI仍是TACE后疗效监测的优选方法。
核心结论
- NC-AMRI对TACE后HCC疗效监测具有中等诊断准确性,但诊断效能低于全序列肝脏MRI。
研究设计与样本
- 单中心回顾性研究,纳入2020年1月至2023年5月间接受TACE后行钆塞酸二钠增强MRI的195例HCC患者,共267个TACE治疗后病灶。
- NC-AMRI由全序列MRI模拟生成,采用LI-RADS CT/MRI非放射治疗反应评估算法2024版和LI-RADS CT/MRI诊断算法2018版允许的两个辅助征象。
- 全序列MRI按完整标准判读:治疗后病灶采用LR-TR Viable分类,新发病灶采用LR-5或富血供LR-4或LR-M分类。
关键影像表现/征象
- NC-AMRI评估采用两个辅助征象:轻中度T2高信号或扩散受限。
- 全序列MRI对治疗后活性病灶采用LR-TR Viable分类判定。
- 全序列MRI对新发病灶采用LR-5、富血供LR-4或LR-M分类判定。
诊断标准与关键数值
- 治疗病灶活性肿瘤检测:NC-AMRI病灶敏感度76.5%(62/81),低于全序列MRI的87.7%(71/81),P=.04。
- 治疗病灶活性肿瘤检测:NC-AMRI病灶特异度88.7%(165/186),低于全序列MRI的96.2%(179/186),P=.004。
- 患者肝内总体复发检测:NC-AMRI患者敏感度78.3%(72/92),低于全序列MRI的92.4%(85/92),P=.004。
- 患者肝内总体复发检测:NC-AMRI患者特异度79.6%(82/103),低于全序列MRI的95.1%(98/103),P<.001。
临床应用与阅片要点
- NC-AMRI的T2高信号或扩散受限征象不能替代增强序列,判读时需注意其漏诊风险。
- TACE术后报告中,若仅依据T2信号或DWI判断活性肿瘤,可能低估治疗后残留或复发。
- 92例肝内复发患者中76例存在治疗病灶活性肿瘤,31例出现新发肿瘤,15例两者兼有,报告需分别评估。
局限性
- 单中心回顾性研究设计,存在选择偏倚可能。
- NC-AMRI由全序列MRI模拟生成,并非真实独立扫描所得。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Posttreatment imaging evaluation after local-regional treatment for hepatocellular carcinoma (HCC) is essential for detecting recurrence and guiding retreatment. Purpose To assess the utility of noncontrast abbreviated MRI (NC-AMRI) using ancillary features from the Liver Imaging Reporting and Data System (LI-RADS) algorithms for detecting intrahepatic recurrence of HCC during treatment response monitoring after transarterial chemoembolization (TACE). Materials and Methods This single-center retrospective study included patients with HCC who underwent TACE followed by gadoxetic acid-enhanced liver MRI between January 2020 and May 2023. NC-AMRI simulated from full-sequence MRI was assessed using two ancillary features (mild-moderate T2 hyperintensity or restricted diffusion) permitted in the LI-RADS CT/MRI nonradiation Treatment Response Assessment algorithm version 2024 and LI-RADS CT/MRI diagnostic algorithm version 2018, whereas full-sequence liver MRI was interpreted with complete criteria (LI-RADS treatment response [LR-TR] Viable category for treated lesions; LR-5 or hypervascular LR-4 or LR-M for new lesions). Diagnostic accuracy for detecting viable tumors (per lesion) and overall intrahepatic recurrence (per patient) was evaluated for both NC-AMRI and full-sequence MRI. Results Among 195 patients with 267 TACE-treated lesions (mean age, 64 years ± 9.8 [SD]; 143 men), 92 patients (47.2%) had intrahepatic recurrence, including 76 (39.0%) with viable tumors in 81 treated lesions and 31 patients (15.9%) with newly developed tumors, whereas 15 patients (7.7%) had both. For viable tumors in treated lesions, compared with full-sequence MRI, NC-AMRI demonstrated both lower per-lesion sensitivity (76.5% [62 of 81] vs 87.7% [71 of 81]; P = .04) and specificity (88.7% [165 of 186] vs 96.2% [179 of 186]; P = .004). For overall intrahepatic recurrence per patient, compared with full-sequence liver MRI, NC-AMRI demonstrated both lower sensitivity (78.3% [72 of 92] vs 92.4% [85 of 92]; P = .004) and specificity (79.6% [82 of 103] vs 95.1% [98 of 103]; P < .001). Conclusion NC-AMRI demonstrated moderate diagnostic accuracy for post-TACE treatment response monitoring in patients with HCC, including viable tumors in treated lesions and newly developed tumors, but lower diagnostic accuracy than full-sequence liver MRI. © RSNA, 2026 Supplemental material is available for this article. See also the editorial by Kozaka in this issue.
引用
- Jeon, Joo, Kang, et al. Noncontrast Abbreviated MRI for Post-TACE Treatment Response Monitoring of Hepatocellular Carcinoma Based on Ancillary Features from LI-RADS. Radiology. 2026. PMID: 42411969. doi:10.1148/radiol.252803
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。